Ongoing Clinical Trials for Tetanus
Currently, there is 1 ongoing clinical trial related to tetanus. This trial focuses on testing a booster vaccine that protects against tetanus, along with diphtheria and whooping cough, in healthcare workers who regularly care for infants. The study is being conducted in Finland and aims to understand how well the vaccine strengthens the immune system’s ability to fight these diseases.
Clinical trial locations
Study on the Effectiveness of dTap Vaccine in Boosting Immunity Against Diphtheria, Tetanus, and Whooping Cough in Healthcare Workers
This clinical trial is taking place in Finland and focuses on studying how well a booster vaccination works in healthcare workers who regularly work with infants. The diseases being studied are diphtheria, tetanus, and pertussis, commonly known as whooping cough. The vaccine being tested is called dTap, which is designed to boost the body’s protection against these three serious bacterial infections.
Main inclusion criteria:
- Must be a healthcare worker who regularly works with infants under 12 months old
- Must need a dTap booster vaccination, which is typically given every 5 years
- It must have been more than 4 years since the last dTap vaccination
- Must be willing to attend 2 study visits, complete questionnaires, and provide blood samples
- Both male and female participants are eligible
Main exclusion criteria:
- Cannot have known allergies to any components of the dTap vaccine
- Cannot have received any other vaccines within 4 weeks before the study starts
- Cannot have any serious chronic illnesses that require ongoing medical attention
- Cannot be pregnant or planning to become pregnant during the study period
- Cannot have immune system disorders or be taking medications that affect the immune system, such as steroids
- Cannot have had a previous severe reaction to any vaccine
- Cannot be participating in another clinical trial at the same time
Focus and goal of the trial:
The purpose of this study is to understand how the immune system of healthcare workers responds to the dTap booster vaccine. Participants will receive the vaccine as an injection into a muscle, and their immune response will be measured before and after vaccination. The study involves two visits over a period of 28 days. At the first visit, participants will complete a questionnaire about their health and work environment and provide a blood sample to measure current immunity levels. After receiving the booster vaccination, participants will have a 28-day period during which their body develops an immune response. At the follow-up visit, another blood sample will be taken to assess how well the vaccine worked in boosting immunity.
The study will track changes in the immune system, including measuring the levels of antibodies, which are proteins made by the immune system to fight infections. The results will help determine how well the vaccine works in boosting immunity among healthcare workers who are regularly in contact with infants, a group particularly vulnerable to these diseases.
Investigational drug:
The dTap vaccine is a combination vaccine that helps protect against three serious diseases: diphtheria, tetanus, and pertussis. This vaccine is given as a booster to help strengthen the body’s defense system against these diseases. The vaccine contains inactivated toxins and proteins from the bacteria, which prompt the immune system to produce antibodies. It is administered as an injection, typically given in the upper arm.
Summary
Currently, there is one ongoing clinical trial related to tetanus, located in Finland. This trial is specifically designed for healthcare workers who regularly care for infants and focuses on testing the effectiveness of the dTap booster vaccine. The study aims to measure how well this combination vaccine strengthens immunity against diphtheria, tetanus, and pertussis over a 28-day period following vaccination. The trial provides important information about vaccine response in a population that is regularly exposed to vulnerable infants who may be at risk from these diseases.